Skip to main content

Clinical trial BOS172738

A Phase 1 Study of BOS172738 in Patients with Advanced Solid Tumors with RET Gene Alterations including Non-Small Cell Lung Cancer (NSCLC) and Medullary Thyroid Cancer (MTC)

Organ Multiple
Trial status Trial closed for recruitment
Trial type
Interventional with experimental drug
Phase Trial phase 1
Academic trial Non
Sponsor Boston pharmaceuticals
EudraCT Identifier 2018-002612-27
Inclusion criteria Rearranged during transfection(RET) gene altered malignancy
Last update